Healthcare Business


Is A Generic Nexium Purple Pill For You?

When it comes to drugs being overly advertised, the Purple Pill, or Nexium, has been advertised over and over for years now. Now the question to ask is if a ...
Read Full Story »

3 Biotech Stocks With Upcoming Data That Could Be Huge

Binary events are often the key element in moving a biotech stock higher. Negative binary results or actions can often move shares drastically lower, though. We scan our 24/7 Wall ...
Read Full Story »

UnitedHealth Earnings Rise as Insurer Adjusts to Obamacare

UnitedHealth Group Inc. (NYSE: UNH) reported fourth-quarter and full-year 2014 results before markets opened Wednesday. The health insurance and benefits management firm reported diluted quarterly earnings per share (EPS) of ...
Read Full Story »
Johnson & Johnson Logo

Johnson & Johnson Barely Pulls Through on Strong Pharma Sales

Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter results Tuesday before the market open as $1.27 in earnings per share (EPS) on $18.6 billion in revenue. That was against Thomson ...
Read Full Story »

Merck Is Top DJIA Stock in 2015

Among the 30 stocks that comprise the Dow Jones Industrial Average (DJIA), Merck & Co. Inc. (NYSE: MRK) was among the top performers in 2014, up about 14%, nearly double ...
Read Full Story »
down market

Has eHealth Fallen Too Far?

eHealth Inc. (NASDAQ: EHTH) was devastated in Thursday’s trading as the company announced its preliminary results for its fourth quarter. This appears to be a company that went from being ...
Read Full Story »
health care

Did Ziopharm and Intrexon Run Too Much on an MD Anderson Pact?

When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »

Celgene Expects to More Than Triple Earnings by 2020

Celgene Corp. (NASDAQ: CELG) provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare ...
Read Full Story »

Is the Merger a Great Deal for Tekmira Shareholders?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), in conjunction with OnCore Biopharma, announced that they have agreed to merge and create a new global hepatitis B virus (HBV) company. The focus of ...
Read Full Story »

Has Agenus Run Too Much?

Agenus Inc. (NASDAQ: AGEN), in conjunction with Incyte Corp. (NASDAQ: INCY), announced a global license for the development and commercialization of Agenus’s proprietary Retrocyte Display antibody discovery platform. As a ...
Read Full Story »

The Bullish and Bearish Case for UnitedHealth in 2015

Now that the bull market is nearing its sixth year, investors have to wonder about valuations after exponential gains from the March 2009 bottom. 2014 brought gains of 7.5% in ...
Read Full Story »
Pfizer logo

The Bullish and Bearish Case for Pfizer in 2015

Last year was another great one for a bull market that is nearly six years old. The Dow Jones Industrial Average (DJIA) rose 7.5% and the S&P 500 Index rose ...
Read Full Story »
Money background. Close-up.

Gilead Continues to Recover from Express Scripts Loss

After the markets closed on Thursday, Gilead Sciences Inc. (NASDAQ: GILD) was picked up by Anthem Inc. (NYSE: ANTM) to provide its hepatitis C drug as the primary option for ...
Read Full Story »

Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential

With a strong market rally getting the markets just about back to even to the start of 2015, aggressive investors are looking ahead to fourth-quarter earnings and other catalysts to ...
Read Full Story »